Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Purpose
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Conditions
- Long COVID
- Insulin Resistance
- Insulin Sensitivity
Eligibility
- Eligible Ages
- Between 18 Years and 80 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Ages 18 to 80 - BMI ≥ 25 kg/m2 - not currently pregnant
Exclusion Criteria
Arm 2 (Adipose Tissue Biopsy) exclusions include - pregnancy - prior liposuction - recent change in weight (> 2 kg in one month) - bleeding disorders - anticoagulant use Arm 3 (healthy controls only) exclusions include patients with - major organ disease - diabetes - history of liposuction - bariatric surgery - eating disorders - psychiatric disorders - pregnancy or lactation - recent change in weight (over the past 12 weeks), - use of weight loss medication or oral steroids - hematocrit < 33% - fasting glucose >= 126 mg/dL - blood pressure >160/100 mmHg
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
No Intervention Chart Review (not actively recruiting) |
Chart review of previously consented participants from the entire NIH RECOVER cohort, comprised of 15,000 infected and 2,600 noninfected patients across the country. |
|
Experimental COVID infected and healthy controls |
Participants will perform a needle fat biopsy for tissue harvesting in the subacute phase (15-30d) of Covid-19 infection or as a healthy control. Our goal is 20 COVID-19 infected participants and 10 healthy controls. |
|
Experimental Healthy Controls Only |
We are looking for 20 healthy controls for 2 in-person visits on separate days. 1. An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if the participant is insulin-sensitive or insulin resistant. 2. A Needle Fat Biopsy: After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Patients will have a local anesthetic prior to the procedure. |
|
Recruiting Locations
Palo Alto, California 94305
More Details
- NCT ID
- NCT05833217
- Status
- Recruiting
- Sponsor
- Stanford University